SCHEMBL1679485

SCHEMBL1679485

CCN(CC)CCNC(=O)c1cccc(-c2cnc(N)c(-c3cccc(OC)c3)c2)c1

nearest known ligand 0.65

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PRKD3 O94806 1/20 0.65
PRKD1 Q15139 1/20 0.65
PRKD2 Q9BZL6 1/20 0.65
FYN P06241 8/20 0.60
CHEK2 O96017 2/20 0.56
CHEK1 O14757 1/20 0.51
RAD52 P43351 3/20 0.48
KMT2A Q03164 3/20 0.48
MEN1 O00255 2/20 0.48
TP53 P04637 1/20 0.48
POLB P06746 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
CAMK2D Q13557 1/20 0.48
UBE2N P61088 1/20 0.48
NEK1 Q96PY6 1/20 0.46
DGAT2 Q96PD7 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1679706 0.91 PRKD3 (0.75) PRKD3PRKD1PRKD2FYNCHEK2
SCHEMBL1679588 0.85 PRKD3 (0.72) PRKD3PRKD1PRKD2FYNCHEK2
SCHEMBL1679110 0.85 PRKD3 (0.86) PRKD3PRKD1PRKD2FYNCHEK2
SCHEMBL1679783 0.85 KMT2A (0.51) PRKD3PRKD1PRKD2FYNRAD52
SCHEMBL1679585 0.84 PRKD3 (0.87) PRKD3PRKD1PRKD2FYNCHEK2
SCHEMBL1679478 0.83 PRKD3 (0.77) PRKD3PRKD1PRKD2FYNCHEK2
SCHEMBL1679133 0.83 PRKD3 (0.69) PRKD3PRKD1PRKD2FYNCHEK2
SCHEMBL1679042 0.82 PRKD3 (0.72) PRKD3PRKD1PRKD2FYNCHEK2
SCHEMBL1679437 0.82 PRKD3 (0.72) PRKD3PRKD1PRKD2FYNCHEK2
SCHEMBL1679750 0.80 PRKD3 (0.70) PRKD3PRKD1PRKD2FYNCHEK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098325-A1 PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2011-04-28 US claimed
US-20110098325-A1 PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2011-04-28 US disclosed
US-20110098325-A1 PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2011-04-28 US disclosed
US-20110098325-A1 PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2011-04-28 US disclosed
WO-2008074997-A1 PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098325-A1 PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS PKD2, PKD1, BAZ2B PRKD3 38/4885PRKD1 33/4885PRKD2 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.